关于益丰大药房连锁股份有限公司 的审核中心意见落实函的回复报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二零二三年九月 向不特定对象发行可转换公司债券 上海证券交易所： 贵所于 2023 年 5 月 15 日出具的上证上审（再融资）〔2023〕309 号《关于 益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券的审核中心意 见落实函》（以下简称"落实函"）已收悉，中信证券股份有限公司作为保荐人 （主承销商）（以下简称"中信证券"或"保荐人"），与益丰大药房连锁股份有 限公司（以下简称"公司"、"发行人"、"申请人"）及湖南启元律师事务所（以 下简称"申请人律师"或"发行人律师"）对问询函所列问题认真进行了逐项落 实，现回复如下，请予审核。 如无特别说明，本回复报告中的简称或名词的释义与募集说明书中的相同。 本回复报告的字体代表以下含义： | 黑体（加粗） | 落实函所列的问题 | | --- | --- | | 宋体 | 对落实函所列问题的回复 | 本回复报告中若出现总数与各分项数值之和尾数不符的情况，均为四舍五 入原因造成。 7-1-3-1 | 目 录 | | ...

目 录 | 一、关于商誉……………………………………………………… 第 | 1—65 | 页 | | --- | --- | --- | | 二、关于应收账款…………………………………………………第 | 65—72 | 页 | | 三、关于存货………………………………………………………第 | 72—78 | 页 | | 四、关于发行条件…………………………………………………第 | 78—81 | 页 | | 五、附件……………………………………………………………第 | 82—85 | 页 | | （一）本所营业执照复印件………………………………………第 | 82 | 页 | | （二）本所执业证书复印件………………………………………第 | 83 | 页 | | （三）本所签字注册会计师执业证书复印件………………第 | 84—85 | 页 | 7-2-1-1 关于益丰大药房连锁股份有限公司 公开发行可转债申请文件反馈意见中 有关财务事项的说明 天健函〔2023〕2-177 号 中国证券监督管理委员会： 由中信证券股份有限公司转来的《中国证监会行政许可项目审查一次反馈意 见通知书》(222650 号，以下简称反馈 ...

关于益丰大药房连锁股份有限公司 向不特定对象发行可转换公司债券 申请文件的审核问询函的回复报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二零二三年九月 上海证券交易所： 贵所于 2023 年 3 月 30 日出具的上证上审（再融资）〔2023〕172 号《关于 益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券申请文件的审 核问询函》（以下简称"问询函"）已收悉，中信证券股份有限公司作为保荐人 （主承销商）（以下简称"中信证券"或"保荐人"），与益丰大药房连锁股份 有限公司（以下简称"公司"、"发行人"、"申请人"）、湖南启元律师事务 所（以下简称"申请人律师"或"发行人律师"）及天健会计师事务所（特殊普 通合伙）（以下简称"申报会计师"）对问询函所列问题认真进行了逐项落实， 现回复如下，请予审核。 如无特别说明，本回复报告中的简称或名词的释义与募集说明书中的相同。 | 本回复报告的字体代表以下含义： | | --- | | 黑体（加粗） | 问询函所列的问题 | | --- | --- | | 宋体 | 对问询函所列问题的回复 | | 楷体（加粗） | 对问询函 ...

目 录 | 一、关于公司线上业务情况……………………………………… 第 | 1—19 | 页 | | --- | --- | --- | | 二、关于财务性投资………………………………………………第 | 19—41 | 页 | | 三、附件……………………………………………………………第 | 42—45 | 页 | | （一）本所营业执照复印件………………………………………第 | 42 | 页 | | （二）本所执业证书复印件………………………………………第 | 43 | 页 | | （三）本所签字注册会计师执业证书复印件………………第 | 44—45 | 页 | 7-2-2-1 关于益丰大药房连锁股份有限公司 向不特定对象发行可转换公司债券审核问询函中 有关财务事项的说明 天健函〔2023〕2-178 号 上海证券交易所： 由中信证券股份有限公司转来的《关于益丰大药房连锁股份有限公司向不特 定对象发行可转换公司债券申请文件的审核问询函》(上证上审(再融资)〔2023〕 172 号,以下简称问询函)奉悉。我们已对问询函所提及的益丰大药房连锁股份有 限公司(以下简称益丰大药房或公司)财务事项进行了审慎核查，现汇 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-080 益丰大药房连锁股份有限公司 关于向不特定对象发行可转换公司债券的审核问询 函回复及募集说明书等申请文件更新的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 益丰大药房连锁股份有限公司（以下简称"公司"）于 2023 年 3 月 4 日在上 海证券交易所（以下简称"上交所"）网站（http://www.sse.com.cn）披露了《益 丰大药房连锁股份有限公司向不特定对象发行可转换公司债券募集说明书》等相 关文件。 根据本次发行项目进展，本公司按照相关要求会同相关中介机构对审核问询 函回复及募集说明书等申请文件的财务数据及其他变动事项更新至 2023 年半年 度，具体内容详见本公司同日在上交所网站（http://www.sse.com.cn）披露的《益 丰大药房连锁股份有限公司向不特定对象发行可转换公司债券募集说明书》等相 关文件。 公司本次向不特定对象发行可转换公司债券事项尚需通过上交所审核，并获 得中国证券监督管理委员会（以下简称"中国 ...

中信证券股份有限公司 关于 益丰大药房连锁股份有限公司 向不特定对象发行可转换公司债券 之 上市保荐书 保荐人（主承销商） 益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券 上市保荐书 声 明 中信证券股份有限公司接受益丰大药房连锁股份有限公司的委托，担任益丰 大药房连锁股份有限公司向不特定对象发行可转换公司债券的保荐人，为本次发 行出具上市保荐书。 保荐人及指定的保荐代表人根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上海 证券交易所股票上市规则》（以下简称"《股票上市规则》"）等有关法律、法 规和中国证券监督管理委员会（以下简称"中国证监会"）、上海证券交易所（以 下简称"上交所"）的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业 务规则、行业执业规范和道德准则出具上市保荐书，并保证所出具文件的真实性、 准确性和完整性。 3-2-1 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二三年九月 益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券 上市保荐书 释 义 本上市保荐书中，除非文义另有所指，相关用语具 ...

益丰大药房连锁股份有限公司 2023 年第三次临时股东大会会议资料 益丰大药房连锁股份有限公司 2023 年第三次临时股东大会 会议资料 2023 年 9 月 1 / 9 益丰大药房连锁股份有限公司 2023 年第三次临时股东大会会议资料 目 录 | 2023 年第三次临时股东大会会议议程 | 3 | | --- | --- | | 2023 年第三次临时股东大会会议须知 | 5 | | 2023 年第三次临时股东大会会议议案 | 6 | | 议案一：关于延长公司向不特定对象发行可转换公司债券方案有效期的议案 | 6 | | 议案二：关于提请股东大会延长授权董事会办理本次向不特定对象发行可转换公司 | | | 债券相关事宜有效期的议案 | 7 | | 议案三：关于公司前次募集资金使用情况专项报告（截至 2023 年 6 月 30 日）的议 | | | 案 | 8 | | 议案四：关于为子公司申请银行授信提供担保的议案 | 9 | 2 / 9 益丰大药房连锁股份有限公司 2023 年第三次临时股东大会会议资料 益丰大药房连锁股份有限公司 2023 年第三次临时股东大会会议议程 会议时间：2023 年 9 月 1 ...

证券代码:603939 证券简称:益丰药房 益丰大药房连锁股份有限公司 投资者关系活动会议纪要 一、会议基本情况 1、 会议时间:2023 年 8 月 30 日、8 月 31 日 2、 会议方式:电话会议 3、 参会人员: 公司参会人员: 董事长 高毅 副总裁 汪飞 万雪梅 王永辉 助理总裁 颜俊 财务总监 邓剑琴 董事会秘书 范炜 机构参会人员:中信证券、东北证券、海通证券、中信建投证券、招商证券、 华泰证券、国金证券、广发证券、方正证券、华创证券、太平洋证券、东海证券、 华安证券、西南证券、中航证券、财信证券、国海证券、上海证券、东海证券、 安信证券、中银国际证券、博时基金、中金基金、富国基金、Fidelity 富达基金、 博道基金、银华基金、长信基金、华宝基金、华平基金、国融基金、中加基金、 鹏扬基金、华富基金、上海方物私募基金、红土创新、磐厚蔚然(上海)私募基 金、摩根士丹利、国金医药、招银国际、北京尚艺投资、阳光资产管理、伊萨投 资、青骊投资、深圳鑫然投资、北京东方睿石投资、建信金融资产投资、中国国 际金融、上海泽茂投资、天安人寿保险、润晖投资、敦和资产、广州市航长投资、 上海伯兄投资、彼得明奇、厦 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥10,706,563,008.05, representing a 22.36% increase compared to ¥8,750,033,435.18 in the same period last year[20]. - The net profit attributable to shareholders increased by 22.33% to ¥705,153,553.66, up from ¥576,424,736.43 in the previous year[20]. - The net profit after deducting non-recurring gains and losses rose by 21.36% to ¥678,767,966.92, compared to ¥559,318,987.64 in the same period last year[20]. - The company generated a net cash flow from operating activities of ¥1,407,732,764.48, which is a 28.76% increase from ¥1,093,287,887.73 in the previous year[20]. - Basic earnings per share increased by 22.81% to ¥0.70, compared to ¥0.57 in the same period last year[21]. - The weighted average return on net assets rose to 7.95%, up from 7.46% in the previous year[21]. - The company's total revenue for the reporting period reached 1,070,656.30 million yuan, representing a year-on-year growth of 22.36% driven by both organic growth from existing stores and rapid expansion of the franchise business[45]. - The net profit attributable to shareholders increased by 22.33%, while the net profit excluding non-recurring gains and losses rose by 21.36% compared to the previous year[46]. - The company achieved a significant reduction in liabilities, decreasing by 5.28% to 1,128,847.87 million yuan compared to the end of the previous year[53]. Store Expansion and Operations - The total number of stores increased by 1,312 to a total of 11,580 stores, including 2,491 franchise stores, as of the end of the reporting period[21]. - The company opened 1,423 new stores during the reporting period, including 692 self-built stores, 202 acquired stores, and 529 franchise stores[21]. - As of June 30, 2023, the company operates 11,580 chain pharmacies across ten provinces, with a net increase of 1,312 stores compared to the previous period[46]. - The company operates 9,089 direct stores, with 7,858 of them qualifying as "medical insurance designated retail pharmacies," accounting for 86.46% of the total store count[57][58]. - The company has established seven modern logistics centers in various provinces, enhancing its supply chain capabilities and supporting rapid expansion[42]. Market and Industry Trends - The retail pharmacy industry in China saw a sales increase from 1,253.8 billion in 2013 to 501.5 billion in 2022, with a compound annual growth rate of 8.2% for retail pharmacies[31]. - The number of retail pharmacies in China reached 623,300 in 2022, an increase of approximately 33,600 from 2021, with a chain rate of 57.76%[31]. - The Chinese retail pharmacy market is expected to continue expanding due to increasing health awareness and government policies promoting retail pharmacy services[29][30]. - The retail pharmacy industry is experiencing a trend towards consolidation, with national and regional leaders leveraging capital to accelerate integration[33]. - The government has introduced policies to include retail pharmacies in outpatient management, creating new growth opportunities for the industry[30]. Strategic Initiatives - The company focuses on a "new retail" strategy, integrating online and offline operations through CRM and big data, aiming to innovate in internet healthcare and prescription flow[44]. - The company has established its own pharmaceutical production subsidiary to meet internal demand for traditional Chinese medicine[28]. - The company has adopted a strategy of "new openings + acquisitions + franchising" to enhance its store network and maintain competitive advantages[75]. - The company emphasizes a "regional focus and steady expansion" strategy, which has led to increased customer satisfaction and repeat purchase rates, contributing to sustained sales growth[47]. Financial Management and Compliance - The company reported a commitment to avoid any competition with its subsidiaries and has established a long-term agreement to ensure no similar business activities are conducted[98]. - The company guarantees that any assets or businesses sold will be offered to its subsidiaries under conditions no less favorable than those offered to third parties[99]. - The company has confirmed that there are no significant related party transactions with its subsidiaries as of the date of the commitment letter[99]. - The company has committed to fair pricing principles in its related transactions, ensuring that prices do not deviate significantly from market averages[108]. - The company has maintained a commitment to transparency and compliance in its financial dealings[108]. Research and Development - The company reported an increase in research and development expenses to ¥9,857,000.57 from ¥9,201,229.80, indicating a focus on innovation[141]. - The company is focusing on enhancing its research and development capabilities to drive future growth, with an emphasis on new technologies[157]. - The company is investing 1 billion in research and development for new technologies aimed at enhancing user experience[163]. Shareholder and Governance Matters - The company held its first extraordinary general meeting in 2023, where shareholders representing 68.65% of voting rights approved three key proposals, including issuing convertible bonds[83]. - The annual shareholder meeting held on May 18, 2023, had 36 attendees representing 487,281,753 shares, accounting for 67.5181% of the total voting rights[84]. - The company did not propose any profit distribution or capital reserve increase for the first half of 2023, with no dividends or stock bonuses planned[86]. - There were changes in senior management, with the appointment of two new vice presidents and one assistant vice president[85]. Financial Position and Assets - The company's total assets at the end of June 2023 amounted to 10,103,865,902 RMB, up from 10,000,000,000 RMB at the end of 2022[172]. - The total liabilities at the end of the first half of 2023 were approximately 4.08 billion, which is consistent with the previous year's figures[160]. - The company's total equity attributable to shareholders at the end of the first half of 2023 was approximately 8.56 billion, up from 8.55 billion at the end of 2022, reflecting a slight increase[160]. Risks and Challenges - The company faces risks from industry policy changes, which may require adjustments in management and operations to mitigate potential operational risks[73]. - The competitive landscape in the pharmaceutical retail industry is intensifying, with large chain enterprises expanding through mergers and acquisitions, increasing market concentration and competition[74]. - There is a risk that acquired stores may not meet performance expectations due to various external factors, which could lead to goodwill impairment[77]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has adhered to environmental protection laws without any violations or penalties[89]. - The company has implemented energy-saving measures, including controlling air conditioning usage and promoting a "green office" initiative with over 30,000 users in its collaborative management system[90]. - The company has adopted eco-friendly materials and technologies in store renovations to optimize resource usage and minimize environmental impact[91].

益丰大药房连锁股份有限公司于 2023 年 8 月 30 日披露了《关于 2022 年限 制性股票激励计划预留授予激励对象名单（预留授予日）》，现将名单更正如下： 原披露为： 证券代码：603939 证券简称：益丰药房 公告编号：2023-079 益丰大药房连锁股份有限公司 关于2022年限制性股票激励计划预留授予激励对象 名单（预留授予日）的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 限制性股票激励计划预留授予分配情况 | 姓名 | | 职位 | 获授的限制性股 | 获授限制性股票占授 | 获授限制性股票占当 | | --- | --- | --- | --- | --- | --- | | | | | 票数量（万股） | 予总量的比例 | 前总股本比例 | | 万雪梅 | | 高级管理人员 | 4.725 | 0.9978% | 0.0047% | | 张朝旭 | | 高级管理人员 | 6.75 | 1.4255% | 0.0067% | | 颜 | 俊 | 高级管理人员 | 2.70 | 0.5 ...